Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116376 · ClinicalTrials.gov registry record · Phase 1
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00116376 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 64 participants.
The verdict
NCT00116376, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against the ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will assess the safety, pharmacokinetic/pharmacodynamic (PK/PD) profiles and clinical activity of AEE788 in a recurrent GBM population.
Interventions
- DRUG AEE788
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116376
The ClinicalTrials.gov registry entry for NCT00116376 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AEE788 is the first listed.
NCT00116376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116376 about?
NCT00116376 is a clinical study titled "Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)". AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against the ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will assess the safety, ph...
What is the current status of trial NCT00116376?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2004-01. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00116376?
The interventions under investigation include: AEE788 (DRUG).
Who is sponsoring clinical trial NCT00116376?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.